KINOX™ is a precise nitric oxide blend for the treatment of term and near-term (>=34 weeks) neonates with a hypoxic respiratory failure, associated with clinical or echocardiographic evidence of pulmonary hypertension. It improves the oxygenation and reduces the need for extracorporeal membrane oxygenation.
SoKINOX™ is the new delivery device designed to bring easy-to-use inhaled nitric oxide (KINOX™) to the next level:
SoKINOX™ functions with most ventilation modes, for all types of patients, thanks to its reliable flow sensor.
The large tactile screen provides clear and organized information, making the device intuitive and controlled through the alarms which are in place.
Its compact design includes a hand-bagging KINOX™ administration system in case of emergency, transfer, or alveolar recruitment.
SoKINOX™ is connected to 2 cylinders with an automatic switch to guarantee treatment continuity.
Air Liquide Healthcare’s mission is to protect vulnerable lives, and with the launch of our fully approved inhaled nitric oxide offer, we introduce yet another means to achieve our goal.
Our portfolio is designed for medical gas therapies
We work backwards from patient therapy - through the supply chain, distribution, and production.
We look for ways to improve patient outcomes, in a relentless desire to protect vulnerable lives, constantly discovering customer pain points and working to provide innovative solutions like Total Gas Management, aerALin quality control, and Intelli-OX.
Innovation is our vision: we prioritize quality of care through patient-centric products and services
We are the only company involved from production to patient therapy, and know medical gases well
Ensuring the safety of your patients and staff is our top priority
We design our products to ensure safety, quality and regulatory compliance for patients, users and employees